Written by Tely Publisher in Post-Market Clinical Follow-Up Insights
Investigational Device Exemption: A Sponsor’s Overview
Updated October 6, 2026
An investigational device exemption (IDE) is an FDA authorization that permits sponsors to conduct clinical investigations of unapproved medical devices in the United States. Not every study needs one: the FDA exempts certain diagnostic, custom, and pre-1976 devices from the requirement. For studies that do require a full IDE, the FDA has 30 days to act on the application. This guide walks you through the decision sequence, from checking whether your investigation qualifies for an exemption to understanding what happens after you submit.
What Is an Investigational Device Exemption (IDE)?
An investigational device exemption is the legal mechanism that allows a sponsor to ship and use an unapproved medical device in a clinical investigation without violating the Federal Food, Drug, and Cosmetic Act. The authority comes from 21 CFR Part 812, which sets out who must apply, what the application must contain, and what obligations apply once the FDA grants approval.
Without an IDE, a sponsor cannot legally run the study that generates the evidence required for eventual clearance or approval.
Understanding where the IDE fits means understanding the FDA's three-tier device classification system. Class I devices carry the lowest risk and are generally exempt from premarket review. Class II devices typically reach the market through the 510(k) clearance process, which requires a sponsor to show substantial equivalence to a legally marketed predicate. Class III devices, including life-sustaining implants such as pacemakers, carry the highest risk and require Premarket Approval (PMA), the most rigorous FDA pathway. Clinical investigations of Class III devices, and of Class II devices that have not yet been cleared, almost always require a full IDE.
The IDE is sometimes compared to an Investigational New Drug (IND) application in the drug and biologic world. Both authorize human studies of unapproved products, and sponsors pursuing combination products or novel drug-device combinations may encounter both pathways. They are not interchangeable.
The FDA's Center for Devices and Radiological Health (CDRH) administers the IDE program. Sponsors can research device classification and existing approvals using the FDA's 510(k) Cleared Database, PMA Database, and De Novo Database before deciding which pathway applies to their device.
Does Your Investigation Require an IDE? Exemption Criteria Explained
Not every clinical investigation of a device triggers the full IDE requirement. The FDA defines several exempt categories in 21 CFR Part 812.2(c), and screening against them is the first concrete step a sponsor should take.
The exemption categories include:
-
Legally marketed devices used within their cleared or approved labeling. If a device already holds 510(k) clearance, PMA approval, or De Novo authorization, and the study uses it exactly as the label specifies, no IDE is required. The device is already legally marketed for that use.
-
Noninvasive diagnostic devices. Devices that do not contact the patient or that contact only intact skin, and that collect diagnostic data without posing significant risk, are generally exempt. The FDA's guidance specifies additional conditions, including that the device not be used as a diagnostic procedure without confirmation by another medically established method where appropriate.
-
Custom devices. A device manufactured to meet the unique needs of an individual patient may qualify as a custom device and be exempt from IDE requirements. Critically, custom devices are restricted to a maximum of five units per year for any specific device type. Sponsors who anticipate needing more than five units for a given device type cannot rely on this exemption.
-
Pre-1976 devices. Devices that were in commercial distribution before May 28, 1976, and have not been significantly changed or modified since, may be exempt. This category is narrow and fact-specific; sponsors should verify applicability carefully before relying on it.
-
Consumer preference testing and other low-risk investigations. Studies that pose no significant risk to participants and that do not collect safety or effectiveness data intended to support a marketing application may also be exempt.
If your investigation falls outside these categories, or if you are uncertain whether it does, proceed as if an IDE is required and conduct the Significant Risk/Non-Significant Risk (SR/NSR) assessment described in the next section. Sponsors who want a formal agency position before investing in a full application can request a Pre-Submission (Pre-Sub) meeting with the FDA. That meeting allows the agency to comment on the proposed study design and risk classification before an application is filed.
For a practical walkthrough of the application process at the country level, the linked resource covers submission mechanics in detail.
Significant Risk vs. Non-Significant Risk Devices: How to Tell the Difference
Once a sponsor confirms that an IDE is required, the next determination is whether the device is a Significant Risk (SR) or Non-Significant Risk (NSR) device. That classification controls the regulatory pathway that follows.
The FDA defines an SR device as one that meets at least one of four criteria: it is an implant; it is life-supporting or life-sustaining; it is substantially important in diagnosing, curing, mitigating, or treating a disease or condition, or preventing impairment to human health; or it presents a potential for serious risk to the health, safety, or welfare of a subject. A cardiac assist device, a spinal implant, or a ventilator would each qualify as SR under one or more of these criteria.
NSR devices are those that do not meet any of the four SR criteria. Studies of NSR devices follow what the FDA calls the abbreviated IDE pathway. Under this pathway, a sponsor does not submit a formal IDE application to the FDA. Instead, the sponsor submits the risk determination and supporting rationale directly to the Institutional Review Board (IRB). If the IRB agrees with the NSR determination and approves the study, the investigation may proceed under abbreviated requirements, which include reduced record-keeping and reporting obligations compared to a full IDE.
The abbreviated pathway still carries real compliance obligations. Sponsors must maintain records of the investigation, ensure devices are labeled for investigational use only, and report certain unanticipated adverse effects. The reduction in burden is meaningful, but oversight does not disappear.
The IRB plays a central role in confirming the sponsor's risk determination. A sponsor may conclude that its device is NSR, but if the IRB disagrees and classifies it as SR, the sponsor must either obtain a full FDA IDE or modify the investigation to address the IRB's concerns. Sponsors should present a clear written rationale for their SR/NSR determination when submitting to the IRB, referencing the four FDA criteria and any available bench or preclinical data that supports the classification.
For devices that involve significant departure from existing models, the SR classification is more likely, and a full IDE application will almost certainly be required. Sponsors in that position should also consider whether the device's novelty warrants a Pre-Sub meeting before the formal application is filed. Detailed guidance on regulatory consulting for novel devices is available through master medical device regulatory consulting in Latin America.
How to Submit an IDE Application to the FDA
Submitting a full IDE application is required when your device is classified as Significant Risk and does not qualify for any exemption. The FDA has 30 days to review a full IDE application and must either approve it, approve it with conditions, or disapprove it within that window.
Follow these steps in order:
-
Identify the investigation as a device study. Confirm that the proposed investigation is designed to assess the safety or effectiveness of a medical device, as defined under 21 CFR Part 812.3(h). If the primary purpose is to evaluate a drug or biologic that happens to incorporate a device component, IND research requirements under 21 CFR Part 312 may apply instead.
-
Screen for exemptions. Work through the exemption categories in 21 CFR Part 812.2(c), as described in the earlier section. Document your reasoning in writing. If any exemption applies, you do not need to proceed further with a formal IDE application.
-
Conduct the SR/NSR assessment. Apply the four FDA criteria for Significant Risk. Prepare a written rationale that references your device's design, intended use, and any available preclinical data.
-
Submit the risk determination to the IRB. The IRB must review and confirm your SR/NSR assessment before you submit to the FDA. If the IRB agrees the device is SR, proceed to step 5.
-
Prepare and submit the full IDE application package. A complete IDE application must include:
- A device description covering design, components, materials, and principles of operation
- The proposed investigational plan, including study objectives, study design, risk and benefit analysis, and a description of how the study will be monitored
- A manufacturing and quality control section demonstrating that the device can be produced consistently
- Investigator qualifications for each participating site
- Informed consent procedures and the consent document template
- An IRB review status letter confirming that the IRB has reviewed the protocol
- An adverse event reporting plan that specifies how unanticipated adverse effects, device defects, and malfunctions will be reported to the FDA, IRBs, and investigators
- Prior investigations, including any prior clinical or nonclinical data relevant to the device
The FDA accepts full IDE applications through its eSTAR electronic submission portal. eSTAR is a structured PDF-based tool that guides sponsors through the required fields and helps ensure the application is complete before submission. Sponsors who have not used the portal before should review the FDA's eSTAR resources and consider requesting a Pre-Sub meeting to align on content expectations before filing.
The 30-day review clock starts when the FDA receives a complete application. If the FDA does not act within 30 days, the IDE is considered approved by default. The FDA has granted approximately 60 Early Feasibility Study (EFS) IDEs annually since 2017, a consistent but selective pipeline that reflects how many novel device investigations clear this process each year.
For sponsors working through the application process for the first time, early engagement with a regulatory affairs team familiar with CDRH expectations reduces the risk of a deficiency letter that restarts the review clock.
IRB Responsibilities During an IDE Study
The Institutional Review Board is an independent ethics committee that operates separately from the FDA. Its approval is required for both SR and NSR device investigations, and its authority runs throughout the life of the study, not just at the start.
Before a study begins, the IRB reviews the full protocol, the informed consent document, any recruitment materials, and the investigator brochure. It evaluates whether risks to participants are minimized and whether they are reasonable in relation to anticipated benefits. The IRB also confirms that participant selection is equitable and that the consent process gives subjects enough information to make a voluntary, informed decision.
Once the study is underway, the IRB conducts continuing review at intervals it sets, typically at least annually. It reviews adverse event reports, protocol amendments, and any new information that could affect the risk-benefit balance. The IRB has authority to suspend or terminate a study if it determines that participants are being exposed to unexpected harm.
The IRB's role in risk classification is particularly important for sponsors. As noted in the SR/NSR section, if a sponsor submits an NSR determination and the IRB disagrees, the investigation cannot proceed without either a full FDA IDE or a redesign that resolves the IRB's concern. The IRB's written determination becomes part of the study record and must be maintained by the sponsor.
One distinction sponsors sometimes overlook: IRB approval and FDA IDE approval are separate authorizations. Receiving one does not substitute for the other. For SR device studies, both are required before the investigation may begin. For NSR studies, IRB approval alone is sufficient, but the sponsor must still meet the abbreviated IDE obligations described earlier.
For a detailed look at how IRB and regulatory approval timelines interact in practice, the guide on the medical device in question covers the IDE process in a specific country context.
Labeling, Advertising, and Monitoring Requirements for IDE Studies
Once an IDE is approved, or once an NSR study is cleared to proceed by the IRB, a defined set of ongoing compliance obligations takes effect. These requirements apply for the duration of the study.
Labeling. Every investigational device must bear a label that states "CAUTION: Investigational Device. Limited by Federal (or United States) law to investigational use." The label must also include the name and address of the manufacturer or distributor. No other claims about the device's safety or effectiveness may appear on the label or in any accompanying materials.
Advertising. Sponsors may not promote or commercialize an investigational device. This means no advertising to patients or clinicians, no sales activity, and no representations that the device is safe or effective for the intended use. The prohibition covers all channels, including digital and social media.
Monitoring. Sponsors are responsible for monitoring each investigational site to verify that the study is conducted according to the approved protocol and that investigators are meeting their obligations. Site monitoring visits should be documented, and any deviations must be addressed promptly.
Adverse event reporting. Sponsors must report unanticipated adverse device effects to the FDA and to all reviewing IRBs within 10 working days of first receiving notice of the effect. Device defects and malfunctions that could cause or contribute to a serious injury must also be reported. These reports feed into the FDA's ongoing safety assessment of the investigation and can trigger a clinical hold if the agency determines that participants face unreasonable risk.
A missed adverse event report within the 10-day window can trigger a clinical hold, halting enrollment and delaying the entire program by weeks or months. Both outcomes cost far more time and capital than proactive compliance.
Planning Your IDE Pathway: How a CRO Can Help
A sponsor who files an SR IDE without a Pre-Sub meeting risks a deficiency letter that restarts the 30-day review clock, adding weeks to the timeline when capital runway is already tight. The choice between pursuing a Pre-Sub meeting, filing a full IDE, or relying on an abbreviated NSR pathway shapes protocol design, site selection, and the structure of the clinical evidence package. Getting those decisions right before the FDA review clock starts is where early CRO engagement pays off.
A contract research organization with CDRH experience can help sponsors align on the IDE or IND research pathway before a single page of the application is drafted. That alignment covers the SR/NSR determination, the study design, and the specific data the FDA will expect to see in the application package. It also covers whether a Pre-Sub meeting is warranted and how to frame the questions to get actionable FDA feedback.
bioaccess® is a Miami-headquartered CRO serving MedTech, biopharma, and radiopharma sponsors. Its FIH-12™ program is a nine-workstream, 12-month engagement that covers FDA Pre-Sub and IDE/IND pathway alignment, protocol development, site activation, patient enrollment, data management, and delivery of a submission-ready clinical evidence package. The program is structured so that data collected under ISO 14155 and formatted per FDA 21 CFR Part 812.28 is accepted for U.S. IDE submissions.
Early engagement with a CRO that understands both the regulatory framework and the operational realities of running first-in-human and early feasibility studies reduces IDE preparation time and lowers the risk of a deficiency letter that delays the program.
Prices and plan limits verified as of October 2026.
FAQs
What is an FDA investigational device?
An FDA investigational device is a medical device that has not yet received FDA clearance or approval for the intended use under study. It is authorized for use in a clinical investigation only through an IDE or, for NSR devices, through IRB approval under the abbreviated IDE pathway. The device must be labeled "for investigational use only" and cannot be commercially distributed during the investigation.
Does every clinical trial involving a medical device require an IDE?
No. Investigations that use a legally marketed device within its cleared or approved labeling do not require an IDE. Other exempt categories include noninvasive diagnostic devices meeting specific FDA criteria, custom devices capped at five units per year per device type, and certain pre-1976 devices. Studies involving NSR devices do not require a formal FDA IDE application, though IRB approval is still mandatory.
What happens if a sponsor disagrees with the FDA’s risk classification of their device?
A sponsor may request reconsideration from the FDA in writing, providing additional data or argument to support a different classification. If the FDA maintains its position, the sponsor must either comply with the SR requirements, modify the investigation to reduce risk, or withdraw the application. Engaging a regulatory affairs team before filing reduces the likelihood of a classification dispute that delays the study.
Can an IDE be used for a device that is already 510(k) cleared?
Yes, but only when the proposed investigation uses the device outside its cleared labeling, such as for a new indication, a new patient population, or a modified procedure. Using a 510(k)-cleared device within its approved labeling does not require an IDE. Sponsors should document the specific departure from cleared use when preparing the IDE application.
How long does an IDE approval remain valid?
An approved IDE remains in effect for the duration of the investigation, provided the sponsor continues to meet all reporting and monitoring obligations. The FDA does not impose a fixed expiration date on an IDE, but it may withdraw approval if the sponsor fails to report adverse events, deviates materially from the approved protocol without amendment, or if new safety information indicates that participants face unreasonable risk.
Conclusion
An investigational device exemption is the regulatory authorization that makes clinical investigation of unapproved devices legally possible in the United States. Whether your study requires a full IDE depends on a structured decision sequence: confirm the investigation qualifies as a device study, screen for exemptions, assess SR/NSR status, and engage the IRB before approaching the FDA. For SR devices, the FDA has 30 days to act on a complete application.
The most common source of delay is not the FDA's review clock but the preparation that precedes it. Sponsors who invest in a clear SR/NSR rationale, a well-designed protocol, and complete application documentation before filing consistently move faster than those who treat the IDE as a form to fill out. Start with the exemption screen, document every decision in writing, and engage regulatory expertise early enough to shape the study design, not just the paperwork.
Leave a Reply Cancel reply
Leave a Reply